Financhill
Sell
22

NVO Quote, Financials, Valuation and Earnings

Last price:
$64.31
Seasonality move :
0.61%
Day range:
$64.16 - $65.79
52-week range:
$57.00 - $139.74
Dividend yield:
2.58%
P/E ratio:
19.05x
P/S ratio:
6.58x
P/B ratio:
14.22x
Volume:
8.1M
Avg. volume:
8.1M
1-year change:
-50.53%
Market cap:
$285.8B
Revenue:
$42.1B
EPS (TTM):
$3.38

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NVO
Novo Nordisk AS
$11.9B $0.94 20.82% 11.23% $86.41
BDRX
Biodexa Pharmaceuticals PLC
-- -- -- -- $17.94
DBVT
DBV Technologies SA
$747.8K -$0.18 -- -84.24% $16.06
EVAX
Evaxion AS
-- -$0.58 -100% -90.33% $13.25
NCNA
NuCana PLC
-- -$0.01 -- -99.69% $104.00
VKTX
Viking Therapeutics
-- -$0.44 -- -120.34% $90.26
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NVO
Novo Nordisk AS
$64.31 $86.41 $285.8B 19.05x $1.14 2.58% 6.58x
BDRX
Biodexa Pharmaceuticals PLC
$0.84 $17.94 $4.3M -- $0.00 0% 0.88x
DBVT
DBV Technologies SA
$10.00 $16.06 $273.5M -- $0.00 0% --
EVAX
Evaxion AS
$2.63 $13.25 $16.6M -- $0.00 0% 1.74x
NCNA
NuCana PLC
$0.05 $104.00 $288.9K -- $0.00 0% --
VKTX
Viking Therapeutics
$32.01 $90.26 $3.6B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NVO
Novo Nordisk AS
46.15% 1.553 5.59% 0.54x
BDRX
Biodexa Pharmaceuticals PLC
-- 2.010 -- 1.20x
DBVT
DBV Technologies SA
-- -2.552 -- --
EVAX
Evaxion AS
-- 2.856 -- 2.80x
NCNA
NuCana PLC
-- -1.015 -- --
VKTX
Viking Therapeutics
-- -0.142 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NVO
Novo Nordisk AS
$9.2B $5.5B 53.78% 84.88% 54.06% $1.4B
BDRX
Biodexa Pharmaceuticals PLC
-- -- -160.77% -160.77% -- --
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M
EVAX
Evaxion AS
-- -$3.9M -238.97% -- -54.59% --
NCNA
NuCana PLC
-- -$3.5M -- -- -- -$4M
VKTX
Viking Therapeutics
-- -$55.5M -- -- -- -$31.2M

Novo Nordisk AS vs. Competitors

  • Which has Higher Returns NVO or BDRX?

    Biodexa Pharmaceuticals PLC has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
  • What do Analysts Say About NVO or BDRX?

    Novo Nordisk AS has a consensus price target of $86.41, signalling upside risk potential of 34.36%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 2024.55%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Novo Nordisk AS, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVO
    Novo Nordisk AS
    5 4 1
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
  • Is NVO or BDRX More Risky?

    Novo Nordisk AS has a beta of 0.642, which suggesting that the stock is 35.798% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.

  • Which is a Better Dividend Stock NVO or BDRX?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.58%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVO or BDRX?

    Novo Nordisk AS quarterly revenues are $11B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.05x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.58x versus 0.88x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVO
    Novo Nordisk AS
    6.58x 19.05x $11B $4.1B
    BDRX
    Biodexa Pharmaceuticals PLC
    0.88x -- -- --
  • Which has Higher Returns NVO or DBVT?

    DBV Technologies SA has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
    DBVT
    DBV Technologies SA
    -- -$1.30 --
  • What do Analysts Say About NVO or DBVT?

    Novo Nordisk AS has a consensus price target of $86.41, signalling upside risk potential of 34.36%. On the other hand DBV Technologies SA has an analysts' consensus of $16.06 which suggests that it could grow by 61.39%. Given that DBV Technologies SA has higher upside potential than Novo Nordisk AS, analysts believe DBV Technologies SA is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVO
    Novo Nordisk AS
    5 4 1
    DBVT
    DBV Technologies SA
    1 0 0
  • Is NVO or DBVT More Risky?

    Novo Nordisk AS has a beta of 0.642, which suggesting that the stock is 35.798% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.587, suggesting its less volatile than the S&P 500 by 158.693%.

  • Which is a Better Dividend Stock NVO or DBVT?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.58%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVO or DBVT?

    Novo Nordisk AS quarterly revenues are $11B, which are larger than DBV Technologies SA quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than DBV Technologies SA's net income of -$27.1M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.05x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.58x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVO
    Novo Nordisk AS
    6.58x 19.05x $11B $4.1B
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
  • Which has Higher Returns NVO or EVAX?

    Evaxion AS has a net margin of 37.18% compared to Novo Nordisk AS's net margin of -64.14%. Novo Nordisk AS's return on equity of 84.88% beat Evaxion AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
    EVAX
    Evaxion AS
    -- -$0.50 $74K
  • What do Analysts Say About NVO or EVAX?

    Novo Nordisk AS has a consensus price target of $86.41, signalling upside risk potential of 34.36%. On the other hand Evaxion AS has an analysts' consensus of $13.25 which suggests that it could grow by 403.8%. Given that Evaxion AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion AS is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVO
    Novo Nordisk AS
    5 4 1
    EVAX
    Evaxion AS
    1 0 0
  • Is NVO or EVAX More Risky?

    Novo Nordisk AS has a beta of 0.642, which suggesting that the stock is 35.798% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock NVO or EVAX?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.58%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVO or EVAX?

    Novo Nordisk AS quarterly revenues are $11B, which are larger than Evaxion AS quarterly revenues of $3M. Novo Nordisk AS's net income of $4.1B is higher than Evaxion AS's net income of -$1.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.05x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.58x versus 1.74x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVO
    Novo Nordisk AS
    6.58x 19.05x $11B $4.1B
    EVAX
    Evaxion AS
    1.74x -- $3M -$1.6M
  • Which has Higher Returns NVO or NCNA?

    NuCana PLC has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat NuCana PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
    NCNA
    NuCana PLC
    -- -$0.63 --
  • What do Analysts Say About NVO or NCNA?

    Novo Nordisk AS has a consensus price target of $86.41, signalling upside risk potential of 34.36%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 217929.35%. Given that NuCana PLC has higher upside potential than Novo Nordisk AS, analysts believe NuCana PLC is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVO
    Novo Nordisk AS
    5 4 1
    NCNA
    NuCana PLC
    0 1 0
  • Is NVO or NCNA More Risky?

    Novo Nordisk AS has a beta of 0.642, which suggesting that the stock is 35.798% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.

  • Which is a Better Dividend Stock NVO or NCNA?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.58%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVO or NCNA?

    Novo Nordisk AS quarterly revenues are $11B, which are larger than NuCana PLC quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than NuCana PLC's net income of -$3.1M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.05x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.58x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVO
    Novo Nordisk AS
    6.58x 19.05x $11B $4.1B
    NCNA
    NuCana PLC
    -- -- -- -$3.1M
  • Which has Higher Returns NVO or VKTX?

    Viking Therapeutics has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
    VKTX
    Viking Therapeutics
    -- -$0.41 --
  • What do Analysts Say About NVO or VKTX?

    Novo Nordisk AS has a consensus price target of $86.41, signalling upside risk potential of 34.36%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 181.98%. Given that Viking Therapeutics has higher upside potential than Novo Nordisk AS, analysts believe Viking Therapeutics is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVO
    Novo Nordisk AS
    5 4 1
    VKTX
    Viking Therapeutics
    10 2 0
  • Is NVO or VKTX More Risky?

    Novo Nordisk AS has a beta of 0.642, which suggesting that the stock is 35.798% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.744%.

  • Which is a Better Dividend Stock NVO or VKTX?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.58%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVO or VKTX?

    Novo Nordisk AS quarterly revenues are $11B, which are larger than Viking Therapeutics quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than Viking Therapeutics's net income of -$45.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.05x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.58x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVO
    Novo Nordisk AS
    6.58x 19.05x $11B $4.1B
    VKTX
    Viking Therapeutics
    -- -- -- -$45.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Will Brown Forman Stock Go?
How High Will Brown Forman Stock Go?

On the surface, Brown‑Forman (NYSE: BF.B) is having an unremarkable year.…

Is Bloom Energy Flying Under the Radar?
Is Bloom Energy Flying Under the Radar?

Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 59x

Buy
61
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
55
TLN alert for Jul 19

Talen Energy [TLN] is up 24.44% over the past day.

Sell
48
CRSP alert for Jul 19

CRISPR Therapeutics AG [CRSP] is up 18.22% over the past day.

Buy
83
SOC alert for Jul 19

Sable Offshore [SOC] is up 11.86% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock